PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise

PYC Therapeutics Limited ( (AU:PYC) ) has issued an update.

PYC Therapeutics reported significant first-quarter 2026 progress across its precision medicine pipeline for genetic diseases with no existing treatments. The company advanced all four development programs toward near-term goals, underscoring its strategy to use RNA therapeutics for diseases driven by haploinsufficiency and reinforce its position in the emerging genetic medicines space.

Operationally, PYC strengthened its balance sheet by raising $600 million from a syndicate of global life sciences specialist investors. It also moved its polycystic kidney disease candidate through the single ascending dose stage toward a multiple ascending dose study and secured alignment with the U.S. FDA on a registrational trial design for its RP11 program, de-risking key clinical and regulatory milestones.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a precision medicine biotechnology company focused on developing RNA-based therapies for patients with genetic diseases that currently lack treatment options. The company has a pipeline of four first-in-class drug candidates, three of which are already in human trials, targeting conditions where RNA therapeutics can modulate gene expression effectively.

Average Trading Volume: 1,489,551

Technical Sentiment Signal: Buy

Current Market Cap: A$1.27B

Learn more about PYC stock on TipRanks’ Stock Analysis page.